Louis Moore Bacon's BMRN Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 325,000 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $19.31 M, representing 0.28% of the portfolio. First purchased in 2013-Q3, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in BMRN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 325,000 shares. Largest reduction occurred in Q3 2024, reducing 250,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +325,000 | New Buy | 325,000 | $59.43 |
| Q3 2024 | -250,000 | Sold Out | 0 | $0.00 |
| Q2 2024 | -10,000 | Reduce 3.85% | 250,000 | $82.33 |
| Q1 2024 | +50,000 | Add 23.81% | 260,000 | $87.34 |
| Q4 2023 | +14,800 | Add 7.58% | 210,000 | $96.42 |
| Q3 2023 | +35,200 | Add 22.00% | 195,200 | $88.48 |
| Q2 2023 | +130,000 | Add 433.33% | 160,000 | $86.68 |
| Q1 2023 | -100,000 | Reduce 76.92% | 30,000 | $97.24 |
| Q4 2022 | +76,012 | Add 140.79% | 130,000 | $103.49 |
| Q3 2022 | -20,576 | Reduce 27.60% | 53,988 | $84.78 |
| Q2 2022 | +17,207 | Add 30.00% | 74,564 | $82.87 |
| Q1 2022 | -114,714 | Reduce 66.67% | 57,357 | $77.10 |
| Q4 2021 | +172,071 | New Buy | 172,071 | $88.35 |
| Q1 2016 | -122,000 | Sold Out | 0 | $0.00 |
| Q4 2015 | +122,000 | New Buy | 122,000 | $104.76 |
| Q2 2015 | -27,500 | Sold Out | 0 | $0.00 |
| Q1 2015 | -28,600 | Reduce 50.98% | 27,500 | $124.62 |
| Q4 2014 | +56,100 | New Buy | 56,100 | $90.39 |
| Q4 2013 | -62,500 | Sold Out | 0 | $0.00 |
| Q3 2013 | +62,500 | New Buy | 62,500 | $72.18 |
Louis Moore Bacon's BioMarin Pharmaceutical Investment FAQs
Louis Moore Bacon first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q3 2013, acquiring 62,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held BioMarin Pharmaceutical Inc. (BMRN) for 20 quarters since Q3 2013.
Louis Moore Bacon's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2025, adding 325,000 shares worth $19.31 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 325,000 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $19.31 M.
As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.28% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 325,000 shares, as reported at the end of Q4 2025.